Serum miR-329-3p as a potential biomarker for ischemic stroke: clinical association and in vitro neuroprotection via PTPN1.

Ischemic stroke, a prevalent disorder of the cerebral vasculature, is associated with substantial risks of long-term disability and death. Explore the expression profile, diagnostic and prognostic relevance, and underlying molecular mechanisms of miR-329-3p in ischemic stroke. 126 acute ischemic stroke patients and 92 healthy controls were enrolled. Serum miR-329-3p and PTPN1 mRNA were measured by qRT-PCR. Neurological function was evaluated via NIHSS and 3-month mRS scores. In vitro, OGD/R-induced SH-SY5Y cells were used. Cell proliferation, apoptosis, oxidative stress, inflammation, and PI3K/Akt pathway activity were assessed. The miR-329-3p-PTPN1 interaction was validated, and rescue experiments were performed. miR-329-3p was downregulated in stroke patients, showing good diagnostic efficacy, and negatively correlated with NIHSS and mRS scores. miR-329-3p is significantly associated with the prognosis of patients. In OGD/R cells, miR-329-3p overexpression improved proliferation, reduced apoptosis, alleviated oxidative stress and inflammation, and activated PI3K/Akt. PTPN1 was confirmed as a direct target; its overexpression abolished the neuroprotective effects of miR-329-3p. Serum miR-329-3p is a potential diagnostic and prognostic biomarker for ischemic stroke and exerts in vitro neuroprotection by targeting PTPN1.